Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nibrozetone by EpicentRx for Oral Mucositis: Likelihood of Approval
Nibrozetone is under clinical development by EpicentRx and currently in Phase II for Oral Mucositis. According to GlobalData, Phase II...
Nibrozetone by EpicentRx for Metastatic Colorectal Cancer: Likelihood of Approval
Nibrozetone is under clinical development by EpicentRx and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Nibrozetone by EpicentRx for Central Nervous System (CNS) Tumor: Likelihood of Approval
Nibrozetone is under clinical development by EpicentRx and currently in Phase I for Central Nervous System (CNS) Tumor. According to...
Nibrozetone by EpicentRx for Solid Tumor: Likelihood of Approval
Nibrozetone is under clinical development by EpicentRx and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Nibrozetone by EpicentRx for Small-Cell Lung Cancer: Likelihood of Approval
Nibrozetone is under clinical development by EpicentRx and currently in Phase III for Small-Cell Lung Cancer. According to GlobalData, Phase...